{"product_id":"generic-tucatinib-tukadx","title":"TUKADX (Tucatinib)","description":"\u003cp\u003e\u003cstrong\u003eTucatinib \u003c\/strong\u003e is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. \u003c\/p\u003e\u003ch3\u003eAdvanced or Metastatic Breast Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor (HER2)-positive breast cancer (including brain metastases) in patients who have received ≥1 anti-HER2-based regimens in the metastatic setting\u003c\/p\u003e\u003cp\u003e300 mg PO BID in combination with trastuzumab and capecitabine\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to the full prescribing information for trastuzumab and capecitabine for additional information\u003c\/p\u003e\u003ch3\u003eColorectal Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with trastuzumab for RAS wild-type HER 2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy\u003c\/p\u003e\u003cp\u003e300 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to the full prescribing information for trastuzumab for additional inforation\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eRefer to the full prescribing information for trastuzumab and capecitabine for dosage modifications\u003c\/p\u003e\u003ch4\u003eDose reductions for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst reduction: 250 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eThird reduction: 150 PO BID\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 150 mg PO BID: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDiarrhea\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 without antidiarrheal treatment: Initiate or intensify appropriate medical therapy; hold until recovery to Grade ≤1, then resume at same dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 with antidiarrheal therapy: Initiate or intensify appropriate medical therapy; hold until recovery to Grade ≤1, then resume at same dose or at next lower dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatotoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 2 bilirubin (\u0026gt;1.5 to 3x ULN): Hold until recovery to Grade ≤1, then resume at same dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 ALT or AST (\u0026gt;5 to 20x ULN) OR Grade 3 bilirubin (\u0026gt;3 to 10x ULN): Hold until recovery to Grade ≤1, then resume at next lower dose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003ePermanently discontinue\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eGrade 4 ALT\/AST (\u0026gt;20x ULN) OR Grade 4 bilirubin (\u0026gt;10x ULN)\u003c\/li\u003e\n\u003cli\u003eALT\/AST \u0026gt;3x ULN AND bilirubin \u0026gt;2x ULN\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Hold until recovery to Grade ≤1, then resume at next lower dose level\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCoadministration with strong CYP2C8 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration; if unavoidable, reduce tucatinib to 100 mg PO BID\u003c\/li\u003e\n\u003cli\u003eAfter discontinuing strong CYP2C8 inhibitor for 3 elimination half-lives, resume tucatinib dose taken before initiating inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Use in combination with trastuzumab and capecitabine is not recommended; capecitabine is contraindicated in patients with severe renal impairment\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Reduce to 200 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status of females of reproductive potential before initiating\u003c\/p\u003e\u003ch4\u003eSelect patients for unresectable or metastatic colorectal cancer\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eBased on presence of HER2 overexpression or gene amplification and RAS wild-type\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797950328875,"sku":"RL2320240201950","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-09-1762.jpg?v=1787022151","url":"https:\/\/xomeds.com\/products\/generic-tucatinib-tukadx","provider":"XOMEDS","version":"1.0","type":"link"}